MRI waiting period eliminated for Taxus:
This article was originally published in Clinica
Boston Scientific has received for its drug-eluting stent (DES), Taxus, a new clearance from the US FDA that allows MRI to be performed on patients immediately following the device's implantation. Taxus is the first DES to be approved for immediate MRI exams, the firm claimed, adding that the approval also applied to the bare-metal version of the stent. Coronary stent recipients can now avoid the two-month waiting period previously required before undergoing MRI during the most critical stage of their recovery, said the firm. In a separate announcement, Boston said it has become the first company to offer a full range of DES sizes, with the launch of three large sizes of Taxus (for vessel sizes of between 4-5mm). The new sizes are set for immediate launch in Europe and in other countries outside the US.